However, triple-negative and HER2-positive breast cancer showed a shorter time interval until the onset of BMs than luminal breast cancer (23.5 ± 23.36 months for triple-negative, 19 ± 29.54 months for the HER2 subtype, and 42 ± 45.51 months for luminal subtype; P < .01, Table 1). Here, ERBB2 is linked to breast carcinoma.